瑞舒伐他汀对病窦综合征双腔起搏器治疗患者NT-proBNP及心脏重构的影响

目的:探讨瑞舒伐他汀对病窦综合征(SSS)双腔起搏器治疗患者N末端B型利钠肽原(NT-proBNP)及心脏重构的影响。方法:选择2011年1月至2011年6月青岛大学医学院附属医院心血管内科因SSS住院并行双腔起搏器(DDD)治疗的患者44例,随机均分为瑞舒伐他汀组:术后常规治疗基础上给予瑞舒伐他汀10mg/d,每晚顿服;常规治疗组:常规治疗,不服用瑞舒伐他汀。分别测定两组术前、术后6个月、术后12个月患者NT-proBNP水平、左房内径(LAD)、左心室射血分数(LVEF)、左室舒张末内径(LVEDd)、左室收缩末内径(LVESd)。结果:术后6个月常规治疗组上述指标较术前有好转趋势;瑞舒伐他汀组NT-proBNP、LAD、LVESd、LVEDd较术前明显降低(P<0.05)。术后12个月两组各指标均较术前有明显改善(P均<0.05),且与常规治疗组比较,瑞舒伐他汀组NT-proBNP(341.51±373)pg/ml比(257.09±173)pg/ml]水平显著降低,LAD(3.96±0.84)cm比(3.67±0.40)cm]显著减小(P均<0.05)。结论:瑞舒伐他汀在一定程度上可逆转病窦综合征双腔起搏器植入患者心脏重构,改善心功能。

Influence of rosuvastatin on NT-proBNP and cardiac remodeling in patients with sick sinus syndrome after dual-chamber pacemaker implantation

Objective： To explore influence of rosuvastatin on N terminal pro brain natriuretic peptide （NT - proB-NP） and cardiac remodeling in patients with sick sinus syndrome （SSS） after dual-chamber pacemaker implanta-tion. Methods： A total of 44 patients, who admitted in department of cardiology of affiliated hospital of medical col-lege of Qingdao University because of SSS and received dual-chamber pacemaker （DDD） implantation from Jan 2011 to Jun 2011, were selected and randomly and equally divided into rosuvastatin group （received rosuvastatin 10 mg/d at night based on routine treatment after surgery） and routine treatment group （received routine treatment without rosuvastatin）. NT-proBNP level, left atrial diameter （LAD）, left ventricular ejection fraction （LVEF）, left ven-tricular end-diastolic dimension （LVEDd） and left ventricular end-systolic dimension （LVESd） were measured in both groups before, and 12 months after surgery. Results： Compared with before surgery, there were improvement trend in above indexes after six month in routine treatment group; compared with before treatment, there were sig-nificant decrease in NT-proBNP, LAD, LVESd and LVEDd in rosuvastatin group after six months, P〈0.05 all. Compared with before surgery, all indexes significantly improved in two groups （P〈0.05 all） after 12 months; compared with routine treatment group, there were significant decrease in NT- proBNP level （341.51 ± 373） pg/ ml vs. （257.09 ± 173） pg/ml] and LAD r （3.96 ± 0.84） cm vs. （3.67 ± 0.40） cm] in rosuvastatin group （P〈0.05 all）. Conclusion： Rosuvastatin can reverse cardiac remodeling and improve cardiac function to some extent in pa-tients with sick sinus syndrome after dual-chamber pacemaker implantation.